The Burdens and Uncertainties of Doing What One Should Do

Area of Science:

• Oncology
• Preventive Medicine
• Pharmacology

Background:

• FDA-approved medications exist to lower breast cancer risk in high-risk women.
• Despite proven efficacy and safety, patient and physician uptake of these drugs remains suboptimal.
• National guidelines recommend these agents, yet awareness and understanding are lacking.

Discussion:

• Physicians and patients exhibit insufficient knowledge of breast cancer risk factors, risk assessment, and indications for risk-reducing medications.
• Conditions like ductal/lobular atypia and lobular carcinoma in situ significantly elevate invasive breast cancer risk.
• A knowledge gap hinders the appropriate utilization of available preventive pharmacotherapies.

Key Insights:

• Low adherence to breast cancer risk-reducing drugs stems from inadequate understanding of risk and indications.
• Specific histological findings, such as atypia and LCIS, are high-risk indicators.
• Targeted educational interventions are necessary to bridge the knowledge gap.

Outlook:

• Increased provider and patient education is essential to improve the adoption of breast cancer risk-reducing drugs.
• Future efforts should focus on disseminating information about risk assessment and pharmacotherapy indications.
• Improving understanding can lead to better-informed decisions and potentially reduce invasive breast cancer incidence.